BiotechTube

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

Mar 1, 2005 → Feb 1, 2006

NCT ID
NCT00104247

About sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT00104247. Target conditions include Phenylketonurias.

What happened to similar drugs?

0 of 2 similar drugs in Phenylketonurias were approved

Approved (0) Terminated (0) Active (2)
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
🔄Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00104247Phase 3Completed

Competing Products

7 competing products in Phenylketonurias

See all competitors
ProductCompanyStageHype Score
SapropterinBioMarin PharmaceuticalPre-clinical
23
PegvaliaseBioMarin PharmaceuticalPre-clinical
23
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
32
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
Pegvaliase-PqpzBioMarin PharmaceuticalPre-clinical
23
PalynziqBioMarin PharmaceuticalPre-clinical
30
Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37